Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
Alnylam Pharmaceuticals, Inc. (ALNY) shares rose 1.9% to $272.67 as of July 21, 2026, a modest gain from the prior close of $267.47. BestStocks flagged the session as a major change for ALNY. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ALNY climbed 1.9% to $272.67
ALNY rose 1.9% in its latest session, moving from $267.47 to $272.67.
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.9% session move; ALNY moved +0.59% from $321.59 to $323.50 on 2026-07-08. Weighing against that: Alnylam Pharmaceuticals, Inc. (ALNY) moved -5.54% from $283.15 to $267.47 on 2026-07-17; Alnylam Pharmaceuticals, Inc. (ALNY) moved -3.58% from $298.76 to $288.06 on 2026-07-13. Wall Street's consensus price target sits at $438.50, implying +60.8% upside from $272.67. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 9 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $272.67, up $5.20 (+1.94%) from the previous close of $267.47. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $267.47 and $323.50, and it currently sits about 9% of the way up that band.
Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)
The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $438.50, 60.8% above the recent $272.67. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.
The bullish case
- Wall Street's consensus price target of $438.50 implies +60.8% upside from $272.67.
- The Street's most bullish target is $485.00 (+77.9%).
- Positive 1.9% session move.
- ALNY moved +0.59% from $321.59 to $323.50 on 2026-07-08.
- ALNY moved +2.73% from $313.04 to $321.59 on 2026-07-07.
The bearish case
- Alnylam Pharmaceuticals, Inc. (ALNY) moved -5.54% from $283.15 to $267.47 on 2026-07-17.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ALNY
Frequently asked questions about ALNY
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
ALNY rose 1.9% to $272.67. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ALNY stock rise?
ALNY gained 1.94% ($5.20) versus the prior close of $267.47, last trading at $272.67 on 1.1× average volume.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is estimated for 2026-07-30 — about 9 days away.
What is the analyst price target for ALNY?
The consensus analyst price target for ALNY is $438.50, about 60.8% above the current $272.67. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ALNY-specific materiality thresholds, triggering an evidence check. It draws on 13 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.